TYRNOVO LTD has a total of 18 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2016. It filed its patents most often in EPO (European Patent Office), Australia and Brazil. Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are RC BIOTECHNOLOGIES INC, ARRYS THERAPEUTICS INC and CINDA PHARMA AB.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 3 | |
#2 | Australia | 2 | |
#3 | Brazil | 2 | |
#4 | Canada | 2 | |
#5 | China | 2 | |
#6 | Republic of Korea | 2 | |
#7 | United States | 2 | |
#8 | WIPO (World Intellectual Property Organization) | 2 | |
#9 | Israel | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Therapeutic chemical compounds | |
#4 | Heterocyclic compounds | |
#5 | Acyclic or carbocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Reuveni Hadas | 16 |
#2 | Kupershmidt Lana | 15 |
#3 | Haviv Izhak | 15 |
#4 | Lana Kupershmidt | 3 |
#5 | Izhak Haviv | 3 |
#6 | Hadas Reuveni | 2 |
Publication | Filing date | Title |
---|---|---|
WO2019097503A1 | Combinations of irs/stat3 dual modulators and anti pd-1/pd-l1 antibodies for treating cancer | |
AU2016213972A1 | Combinations of IRS/Stat3 dual modulators and anti-cancer agents for treating cancer |